新辅助化疗在宫颈癌治疗中的应用

Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer

目的评价新辅助化疗在宫颈癌治疗中的效果,为宫颈癌治疗工作的开展提供参考。方法选择我院2016年8月~2018年3月收治的宫颈癌患者60例。以随机数字表法分为对照组和观察组,各30例。对照组接受常规手术治疗,观察组在术前给予新辅助化疗治疗。对比两组宫颈癌患者术中出血量、手术时间、治疗效果以及术后并发症情况、患者治疗效果满意度评分。结果观察组宫颈癌患者手术时间为(144.50±23.50)min,短于对照组的(224.50±28.50)min(P<0.05);术后并发症总发生率为16.67%,低于对照组的6.66%(P<0.05);观察组治疗效果满意度评分(90.02±2.15)分,高于对照组的(75.50±2.80)分(P<0.05);治疗总有效率86.67%,优于对照组的73.33%(P<0.05)。结论宫颈癌治疗中于术前进行新辅助化疗,可以提高患者治疗效果、安全性、缩短手术时间,整体预后效果显著。

Objective To evaluate the effect of neoadjuvant chemotherapy in the treatment of cervical cancer and provide reference for the development of cervical cancer treatment.Methods 60 patients with cervical cancer admitted to our hospital from August 2016 to March 2018 were selected. They were divided into control group and observation group by random number table method, 30 cases each. The control group received routine surgery and the observation group received neoadjuvant chemotherapy before surgery. The intraoperative blood loss, operation time, treatment effect, postoperative complications, and patient satisfaction satisfaction scores of the two groups of cervical cancer patients were compared.Results The operation time of cervical cancer patients was (144.50±23.50) min, which was shorter than that of the control group (224.50±28.50) min (P<0.05). The total incidence of postoperative complications was 16.67%, which was lower than that of the control group 6.66%(P<0.05). The satisfaction score of the treatment group (90.02±2.15) was higher than that of the control group (75.50±2.80)(P<0.05);the total effective rate of treatment was 86.67%, which was better than 73.33% of the control group (P<0.05).Conclusion Neoadjuvant chemotherapy in the treatment of cervical cancer can improve the treatment effect, safety and shorten the operation time. The overall prognosis is significant.